Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.
Jingsong Zhang, MD, PhD
Advertisement
Articles by Jingsong Zhang, MD, PhD
Jingsong Zhang, MD, PhD, discusses the advancements for patients with metastatic castration-resistant prostate cancer (mCRPC) that have occurred over the last decade.
Advertisement
Latest Updated Articles
Dr. Zhang on the State of Risk Stratification in mCRPCPublished: August 30th 2021 | Updated:
Dr. Zhang on Therapeutic Advancements in Prostate CancerPublished: October 7th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5